Association between Nesfatin-1 Levels and C-Peptide in Sera of Obese / Non-Obese Type 2 Diabetic Women
Keywords:Nesfatin-1, C-Peptide, Obese, Diabetes Mellitus, Type 2, Body Mass Index, Hypoglycemic Agents
Objective: The aim of the presented word was to assess the diagnostic accuracy of serum Nesfatin-1 in type 2 diabetes mellitus and its relationship with C-peptide level in obese and non-obese type-2 diabetic women of Iraqi population.
Methods: A case-control study was performed on 50 type 2 diabetic patients admitted in Al-Hussein Teaching Hospital and Al-Hassan center of diabetes and endocrinology unit / Kerbala health directorate – Iraq and another 50 control individuals, during the period from April, 2022 – Jan. 2023). The T2DM groups were divided into two groups 25 obese and 25 non-obese; also the control group was divided into 25 obese and 25 non-obese as apparently healthy groups. The ELISA Kit was used to measure serum Nesfatin-1 and C-peptide, and random serum glucose was measured by enzymatic colorimetric method, and lipid profile test were measured through spectrophotometric technique, instead of HbA1c% was determined using HPLC method.
Results: The results observed indicated that Nesfatin-1 levels shown a non-significant decrease in all of type 2 diabetic groups as compared with apparently healthy control group, while the C-peptide were significantly decreased in type 2 diabetic patients when compared with apparently control group. In addition, the random blood glucose and HbA1c% were shown significant elevation in type 2 diabetic patients as compared with apparently healthy control groups. The observed data indicated that Nesfatin-1 and C-peptide levels when comparing between type 2 diabetic patients and control in obese groups shown a risk factors depending upon the odd ratio observed (OR = 1.064 (1.011-1.119), 1.0200 (0.992-1.08)) respectively, but only Nesfatin-1 was shown to be significant. In BMI the levels of Nesfatin-1 and C-peptide, as shown the Nesfatin-1 was significant in obese groups, while the C-peptide as shown significant in normal weight groups. The optimal diagnostic points for Nesfatin-1 were (sensitivity = 98%, specificity = 90%) at a level (Cut-off points) = 39.13, while C-Peptide levels: (sensitivity = 98%, specificity = 94%) at a level (Cut-off points) = 15.99. Both markers have p-values of the AUC were <0.001 and statistically significant.
Conclusion: Accordingly, it was concluded that a significant relationship between circulating Nesfatin-1 levels and type 2 diabetes. Nesfatin-1 appears to be able to contribute to the treatment of obesity and diabetes because of its anorexigenic and antihyperglycemic effects. In addition, C-peptide is a known biomarker of insulin resistance and beta-cell function. High specificity and sensitivity analyzed results were obtained by ROC analysis for both markers in T2DM.
• Algul, Ozdenk and Ozcelik. (2017). Variations in leptin, nesfatin-1 and irisin levels induced by aerobic exercise in young trained and untrained male subjects. 34(4), 339-344.
• Abusaib M, Ahmed M, Nwayyir HA, Alidrisi HA, Al-Abbood M, Al-Bayati A, Al-Ibrahimi S, Al-Kharasani A, Al-Rubaye H, Mahwi T, Ashor A. Iraqi experts consensus on the management of type 2 diabetes/prediabetes in adults. Clinical Medicine Insights: Endocrinology and Diabetes. 2020 Aug;13:1179551420942232.
• Anwar, Yamamah, Ibrahim, et al. (2014). Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance. 188, 21-24.
• Beshara, Cohen, Goldberg, et al. (2016). Triglyceride levels and risk of type 2 diabetes mellitus: a longitudinal large study. 64(2), 383-387.
• Deepthi, Sowjanya, Lidiya, et al. (2017). A modern review of diabetes mellitus: an annihilatory metabolic disorder. 3(1).
• Dong, Xu, Xu, et al. (2013). Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. 8(12), e83397.
• Farag, & Gaballa. (2011). Diabesity: an overview of a rising epidemic. 26(1), 28-35.
• Gonzalez-Mejia, Porchia, Torres-Rasgado, et al. (2016). C-peptide is a sensitive indicator for the diagnosis of metabolic syndrome in subjects from Central Mexico. 14(4), 210-216.
• Gudbjartsson, Thorgeirsson, Sulem, et al. (2019). Lipoprotein (a) concentration and risks of cardiovascular disease and diabetes. 74(24), 2982-2994.
• Gui, Silha, Mishra, et al. (2003). Changes in adipokine expression during food deprivation in the mouse and the relationship to fasting-induced insulin resistance. 81(10), 979-985.
• Al-Tu'ma, F. J. and Yousuf, L. M. Z. (2015). Vitamin D deficiency and hypertension in type 2 diabetic Iraqi patients. J. Contemp. Med. Sci., 1(1) : 17-20.
• Ikegami, Babaya, and Noso. (2021). β‐Cell failure in diabetes: Common susceptibility and mechanisms shared between type 1 and type 2 diabetes. 12(9), 1526-1539.
• Khalil, Zrieki, & Technology. (2022). Factors associated with Glycemic control among Syrian patients with Type 2 Diabetes Mellitus. 15(4), 1701-1708.
• Khalili, Khaniani, Afkhami, et al. (2017). NUCB2/Nesfatin-1: a potent meal regulatory hormone and its role in diabetes. 18(2), 105-109.
• Kühne, Schalla, Friedrich, et al. (2018). Nesfatin-130-59 injected intracerebroventricularly increases anxiety, depression-like behavior, and anhedonia in normal weight rats. 10(12), 1889.
• Lachin, McGee, Palmer, et al. (2014). Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. 63(2), 739-748.
• Lam, Dayan, & Herold. (2021). A little help from residual β cells has long-lasting clinical benefits. 131(3).
• Leighton, Sainsbury, and Jones. (2017). A practical review of C-peptide testing in diabetes. 8(3), 475-487.
• Li, Wang, Chen, et al. (2010). Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. 159(1-3), 72-77.
• Luppi, Drain, To, et al. (2020). Autocrine C‐peptide protects INS1 β cells against palmitic acid‐induced oxidative stress in peroxisomes by inducing catalase. 3(3), e00147.
• Mohan, Gasner, Ramesh, et al. (2016). Ghrelin, ghrelin-O-acyl transferase, nucleobindin-2/nesfatin-1 and prohormone convertases in the pancreatic islets of Sprague Dawley rats during development. 47, 325-336.
• Nakata, Manaka, Yamamoto, et al. (2011). Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells. 58(4), 305-313.
• Oh-I, Shimizu, Satoh, et al. (2006). Identification of nesfatin-1 as a satiety molecule in the hypothalamus. 443(7112), 709-712.
• Organization. (2016). World health statistics 2016: monitoring health for the SDGs sustainable development goals: World Health Organization.
• Pan, Hsuchou, and Kastin. (2007). Nesfatin-1 crosses the blood–brain barrier without saturation. 28(11), 2223-2228.
• Park, Ihm, Yoo, et al. (1997). Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus. 37(3), 165-171.
• Rickels, Evans-Molina, Bahnson, et al. (2020). High residual C-peptide likely contributes to glycemic control in type 1 diabetes. 130(4), 1850-1862.
• Riva, Nitert, Voss, et al. (2011). Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. 346, 393-405.
• Rye, Barter, and Cochran. (2016). Apolipoprotein AI interactions with insulin secretion and production. 27(1), 8-13.
• Şafak, GÜLÇİÇEK, SKSOY, et al. (2017). Increased Serum Nesfatin-1 Levels in Patients with Impaired Glucose Tolerance. 21(3), 65.
• Samani, Ghasemi, Bookani, et al. (2019). Serum nesfatin-1 level in healthy subjects with weight-related abnormalities and newly diagnosed patients with type 2 diabetes mellitus; a case-control study. 15(1), 69.
• Senin, Al-Massadi, Barja-Fernandez, et al. (2015). Regulation of NUCB2/nesfatin-1 production in rat's stomach and adipose tissue is dependent on age, testosterone levels and lactating status. 411, 105-112.
• Silitonga, Siahaan, & Anto. (2019). Correlation between obesity and lipid profile in Type 2 diabetes mellitus patients at the endocrine and metabolic polyclinic in general hospital pirngadi medan. 7(8), 1309.
• Stern, Rutkowski, and Scherer (2016). Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. 23(5), 770-784.
• Su, Zhang, Tang, et al. (2010). The novel function of nesfatin-1: anti-hyperglycemia. 391(1), 1039-1042.
• Thivolet, Marchand, & Chikh. (2019). Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide. 62, 593-597.
• Tsuchiya, Shimizu, Yamada, et al. (2010). Fasting concentrations of nesfatin‐1 are negatively correlated with body mass index in non‐obese males. 73(4), 484-490.
• Tura, Ludvik, Nolan, et al. (2001). Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. 281(5), E966-E974.
• Wu, Yang, Chen, et al. (2014). Hypothalamic nesfatin-1/NUCB2 knockdown augments hepatic gluconeogenesis that is correlated with inhibition of mTOR-STAT3 signaling pathway in rats. 63(4), 1234-1247.
• Yang, Zhang, Wang, et al. (2012). Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance. 61(8), 1959-1968.
• Yosten, Maric-Bilkan, Luppi, et al. (2014). Physiological effects and therapeutic potential of proinsulin C-peptide. 307(11), E955-E968.
How to Cite
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.